Varma Mutual Pension Insurance Co Has $10.74 Million Holdings in Edwards Lifesciences Corporation $EW

Varma Mutual Pension Insurance Co increased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 7.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 138,058 shares of the medical research company’s stock after acquiring an additional 9,900 shares during the period. Varma Mutual Pension Insurance Co’s holdings in Edwards Lifesciences were worth $10,737,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in EW. Econ Financial Services Corp acquired a new position in shares of Edwards Lifesciences during the second quarter worth $889,000. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its position in Edwards Lifesciences by 7.0% during the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock worth $10,719,000 after purchasing an additional 9,069 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Edwards Lifesciences by 13.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock worth $6,706,000 after buying an additional 10,078 shares during the period. Atlantic Union Bankshares Corp grew its position in shares of Edwards Lifesciences by 2,240.9% in the 3rd quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock valued at $925,000 after buying an additional 11,384 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp increased its stake in shares of Edwards Lifesciences by 97.3% in the second quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock valued at $3,481,000 after buying an additional 21,950 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,386 shares of the company’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $83.76, for a total transaction of $953,691.36. Following the transaction, the vice president owned 38,970 shares in the company, valued at approximately $3,264,127.20. This represents a 22.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,885,571.40. The trade was a 4.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 43,804 shares of company stock worth $3,699,082 in the last ninety days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $75.80 on Friday. The firm has a market capitalization of $43.99 billion, a P/E ratio of 41.42, a P/E/G ratio of 2.00 and a beta of 0.94. The firm’s 50-day moving average price is $83.34 and its 200-day moving average price is $81.08. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.89.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. During the same quarter in the prior year, the business earned $0.59 earnings per share. The business’s quarterly revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on EW shares. Raymond James Financial raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective on the stock in a research note on Monday, November 3rd. Royal Bank Of Canada boosted their price target on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, December 5th. Robert W. Baird set a $90.00 price objective on shares of Edwards Lifesciences in a research report on Monday, January 12th. National Bank Financial set a $92.00 target price on shares of Edwards Lifesciences in a research note on Friday, October 31st. Finally, BTIG Research reaffirmed a “buy” rating and set a $103.00 price target on shares of Edwards Lifesciences in a research report on Wednesday. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $96.14.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.